Predicting drug metabolism induction in silico

Current Topics in Medicinal Chemistry

Volumn 6, Issue 15, 2006, Pages 1627-1640

  Schuster, Daniela ^a   Steindl, Theodora M ^a   Langer, Thierry ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

In silico; Metabolism induction prediction; Molecular modeling; Nuclear receptors

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; AROMATIC HYDROCARBON RECEPTOR; ASTEMIZOLE; CELL NUCLEUS RECEPTOR; CISAPRIDE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLOSPORIN; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; FARNESOID X RECEPTOR; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; LIVER X RECEPTOR; MEVINOLIN; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; PROTEINASE INHIBITOR; RETINOID X RECEPTOR; RIFAMPICIN; RIFAMYCIN; TERFENADINE; TROGLITAZONE; UNINDEXED DRUG;

ABSORPTION; COMPUTER ANALYSIS; COMPUTER MODEL; DEPRESSION; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TRANSPORT; ENZYME ACTIVATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MOLECULAR MODEL; NONHUMAN; PREDICTION; PROCESS MODEL; PROTEIN EXPRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; REVIEW; XENOBIOTIC METABOLISM;

ANIMALS; COMPUTATIONAL BIOLOGY; HUMANS; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 33748150392     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778108924     Document Type: Review

References (155)

1. Johnson, J. A. Drug target pharmacogenomics: an overview. Am. J. Pharmacogenomics 2001, 1, 271-281.
2. Wilkinson, G. R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 2005, 352, 2211-2221.
3. Marzolini, C.; Paus, E.; Buclin, T.; Kim, R. B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004, 75, 13-33.
4. Johnson, J. A.; Lima, J. J. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003, 13, 525-534.
5. Evans, W. E.; McLeod, H. L. Pharmacogenomics-drug disposition drug targets, and side effects. N. Engl. J. Med. 2003, 348, 538-549.
6. Lazarou, J.; Pomeranz, B. H.; Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279, 1200-1205.
7. Delgoda, R.; Westlake, A. C. G. Herbal interactions involving cytochrome P450 enzymes. A mini review. Toxicol. Rev. 2004, 23, 239-249.
8. Zhou, S.; Chan, S. Y.; Goh, B. C.; Chan, E.; Duan, W.; Huang, M.; McLeod, H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 2005, 44, 279-304.
9. Israili, Z. H.; Dayton, P. G. Human alpha-1-glycoprotein and its interactions with drugs. Drug Met. Rev. 2001, 33, 161-235.
10. Rolan, P. E. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br. J. Clin. Pharmacol. 1994, 37, 125-128.
11. Jung, H.; Peregrina, A. A.; Rodriguez, J. M.; Moreno-Esparza, R. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm. Drug. Dispos. 1997, 18, 459-463.
12. Bonate, P. L.; Reith, K.; Weir, S. Drug interactions at the renal level: implications for drug development. Clin. Pharmacokinet. 1998, 34, 375-404.
13. Xu, C.; Li, C. Y.-T.; Kong, A.-N. T. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28, 249-268.
14. Mutschler, E.; Geisslinger, G.; Kroemer, H. K.; Schäfer-Korting, M. Arzneimittelwirkungen. Wissenschaftliche Verlagsgesellschaft mbH: Stuttgart, 2001.
15. Nelson, D. R.; Koymans, L.; Kamataki, T.; Stegeman, J. J.; Feyereisen, R.; Waxman, D. J.; Waterman, M. R.; Gotoh, O.; Coon, M. J.; Estabrook, R. W.; Gunsalus, I. C.; Nebert, D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6, 1-42.
16. Williams, P. A.; Cosine, J.; Ward, A.; Angove, H. C.; Vinkovic, D. M.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003, 424, 464-468.
17. Ekins, S.; Stresser, D. M.; Andrew Williams, J. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 2003, 24, 161-166.
18. Schuster, D.; Laggner, C.; Steindl, T. M.; Langer, T. Development and validation of an in silico P450 profiler based on pharmacophore models. Curr. Drug Discov. Technol. 2006, 3, 1-48.
19. Benoit, G.; Malewicz, M.; Perlmann, T. Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends Cell Biol. 2004, 14, 369-376.
20. Bourguet, W.; Germain, P.; Gronemeyer, H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 2000, 21, 381-388.
21. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
22. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Willson, T. M.; Kliewer, S. A.; Redinbo, M. R. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science 2001, 292, 2329-2333.
23. Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisely, G. B.; Noble, S. M.; Davis-Searles, P. R.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R. 2.1 .ANG. Crystal Structure of Human PXR in Complex with the St. John's Wort Compound Hyperforin. Biochemistry 2003, 42, 1430-1438.
24. Watkins, R. E.; Davis-Searles, P. R.; Lambert, M. H.; Redinbo, M. R. Coactivator Binding Promotes the Specific Interaction Between Ligand and the Pregnane X Receptor. J. Mol. Biol. 2003, 331, 815-828.
25. Chrencik, J. E.; Orans, J.; Moore, L. B.; Xue, Y.; Peng, L.; Collins, J. L.; Wisely, G. B.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R. Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol. Endocrinol. 2005, 19, 1125-1134.
26. Xu, R. X.; Lambert, M. H.; Wisely, B. B.; Warren, E. N.; Weinert, E. E.; Waitt, G. M.; Williams, J. D.; Collins, J. L.; Moore, L. B.; Willson, T. M.; Moore, J. T. A structural basis for constitutive activity in the human CAR/RXRa heterodimer. Mol. Cell 2004, 16, 919-928.
27. Downes, M.; Verdecia, M. A.; Roecker, A. J.; Hughes, R.; Hogenesch, J. B.; Kast-Woelbern, H. R.; Bowman, M. E.; Ferrer, J.-L.; Anisfeld, A. M.; Edwards, P. A.; Rosenfeld, J. M.; Alvarez, J. G. A.; Noel, J. P.; Nicolaou, K. C.; Evans, R. M. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 2003, 11, 1079-1092.
28. Williams, S.; Bledsoe, R. K.; Collins, J. L.; Boggs, S.; Lambert, M. H.; Miller, A. B.; Moore, J.; McKee, D. D.; Moore, L.; Nichols, J.; Parks, D.; Watson, M.; Wisely, B.; Willson, T. M. X-ray Crystal Structure of the Liver X Receptor b Ligand Binding Domain: Regulation by a Histidine-Tryptophan Switch. J. Biol. Chem. 2003, 278, 27138-27143.
29. Farnegardh, M.; Bonn, T.; Sun, S.; Ljunggren, J.; Ahola, H.; Wilhelmsson, A.; Gustafsson, J.-A.; Carlquist, M. The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J. Biol. Chem. 2003, 278, 38821-38828.
30. Svensson, S.; Oestberg, T.; Jacobsson, M.; Norstroem, C.; Stefansson, K.; Hallen, D.; Johansson, I. C.; Zachrisson, K.; Ogg, D.; Jendeberg, L. Crystal structure of the heterodimeric complex of LXR.alpha. and RXRb ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22, 4625-4633.
31. Hoerer, S.; Schmid, A.; Heckel, A.; Budzinski, R.-M.; Nar, H. Crystal Structure of the Human Liver X Receptor b Ligand-binding Domain in Complex with a Synthetic Agonist. J. Mol. Biol. 2003, 334, 853-861.
32. Rochel, N.; Wurtz, J. M.; Mitschler, A.; Klaholz, B.; Moras, D. The crystal structure of the nuclear receptor for vitamm D bound to its natural ligand. Mol. Cell 2000, 5, 173-179.
33. Cronet, P.; Petersen, J. F. W.; Folmer, R.; Blomberg, N.; Sjoblom, K.; Karlsson, U.; Lindstedt, E. L.; Bamberg, K. Structure of the PPARa and -g Ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9, 699-706.
34. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13919-13924.
35. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J. E.; McKee, D. O.; Galardi, C. M.; Plunket, K. D.; Nolte, R. T.; Parks, D. J.; Moore, J. T.; Kilewer, S. A.; Willson, T. M.; Stimmel, J. B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARa. Nature 2002, 415, 813-817.
36. Duda, K.; Chi, Y.-I.; Shoelson, S. E. Structural Basis for HNF-4a Activation by Ligand and Coactivator Binding. J. Biol. Chem. 2004, 279, 23311-23116.
37. Bledsoe, R. K.; Montana, V. G.; Stanley, T. B.; Delves, C. J.; Apolito, C. J.; McKee, D. D.; Consler, T. G.; Parks, D. J.; Stewart, E. L.; Willson, T. M.; Lambert, M. H.; Moore, J. T.; Pearce, K. H.; Xu, H. E. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002, 110, 93-105.
38. Kauppi, B.; Jakob, C.; Faernegardh, M.; Yang, J.; Ahola, H.; Alarcon, M.; Calles, K.; Engstroem, O.; Harlan, J.; Muchmore, S.; Ramqvist, A.-K.; Thorell, S.; Oehman, L.; Greer, J.; Gustafsson, J.-A.; Carlstedt-Duke, J.; Carlquist, M. The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 2003, 278, 22748-22754.
39. Greschik, H.; Moras, D. Structure-activity relationship of nuclear receptor-ligand interactions. Curr. Top. Med. Chem. 2003, 3, 1573-1599.
40. Mankowski, D. C.; Ekins, S. Prediction of human drug metabolizing-enzyme induction. Current Drug Metabolism 2003, 4, 381-391.
41. Lehmann, J. M.; McKee, D. D.; Watson, M. A.; Willson, T. M.; Moore, J. T.; Kliewer, S. A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 1998, 102, 1016-1023.
42. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12208-12213.
43. Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit-Singh, C. J.; Willson, T. M.; Collins, J. L.; Kliewer, S. A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7500-7502.
44. Moore, L. B.; Parks, D. J.; Jones, S. A.; Bledsoe, R. K.; Consler, T. G.; Stimmel, J. B.; Goodwin, B.; Liddle, C.; Blanchard, S. G.; Willson, T. M.; Collins, J. L.; Kliewer, S. A. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 2000, 275, 15122-15127.
45. Jones, S. A.; Moore, L. B.; Shenk, J. L.; Wisely, G. B.; Hamilton, G. A.; McKee, D. D.; Tomkinson, N. C. O.; LeCluyse, E. L.; Lambert, M. H.; Willson, T. M.; Kliewer, S. A.; Moore, J. T. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 2000, 14, 27-39.
46. Tirona, R. G.; Kim, R. B. Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci. 2005, 94, 1169-1186.
47. Xie, W.; Radominska-Pandya, A.; Shi, Y.; Simon, C. M.; Nelson, M. C.; Ong, E. S.; Waxman, D. J.; Evans, R. M. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3375-3380.
48. Xie, W.; Uppal, H.; Saini, S. P. S.; Mu, Y.; Little, J. M.; Radominska-Pandya, A.; Zemaitis, M. A. Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism. Drug Discov. Today 2004, 9, 442-449.
49. Sonoda, J.; Chong, L. W.; Downes, M.; Barish, G. D.; Coulter, S.; Liddle, C.; Lee, C.-H.; Evans, R. M. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 2198-2203.
50. Chen, J.; Raymond, K. Treatment effect of rifampicin on cholestasis. Internet J. Pharmacol. 2005, 3, online.
51. Ekins, S.; Erickson, J. A. A pharmacophore for human pregnane X receptor ligands. Drug Metab. Dispos. 2002, 30, 96-99.
52. Accelrys Catalyst Version 4.5; 4.5 ed.: San Diego, CA.
53. Li, H.; Sutter, J.; Hoffmann, R. HypoGen: An Automated System for Generating 3D Predictive Pharmaophore Models. In Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F.; Eds.; International University Line: La Jolla, CA, 2000; pp 171-189.
54. Jacobs, M. N.; Dickins, M.; Lewis, D. F. V. Homology modeling of the nuclear receptors: human estrogen receptorb (hERb), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human estrogen receptor a (hERa) crystal structure, and the human peroxisome proliferator activated receptor a (PPARa) ligand binding domain from the human PPARg crystal structure. J. Steroid Biochem. Mol. Biol. 2003, 84, 117-132.
55. Jacobs, M. N. In silico tools to aid risk assessment of endocrine disrupting chemicals. Toxicology 2004, 205, 43-53.
56. Schuster, D.; Langer, T. The Identification of Ligand Features Essential for PXR Activation by Pharmacophore Modeling. J. Chem. Inf. Model. 2005, 45, 431-439.
57. Clement, O. O.; Mehl, A. T. HipHop: Pharmacophores Based on Multiple Common-Feature Alignments. In Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F.; Eds.; International University Line: La Jolla, CA, 2000; pp 69-84.
58. Maglich, J. M.; Stoltz, C. M.; Goodwin, B.; Hawkins-Brown, D.; Moore, J. T.; Kliewer, S. A. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 2002, 62, 638-646.
59. Wei, P.; Zhang, J.; Dowhan, D. H.; Han, Y.; Moore, D. D. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J. 2002, 2, 117-126.
60. Moore, J. T.; Moore, L. B.; Maglich, J. M.; Kliewer, S. A. Functional and structural comparison of PXR and CAR. Biochim. Biophys. Acta 2003, 1619, 235-238.
61. Ekins, S.; Mirny, L.; Schuetz, E. G. A Ligand-Based Approach to Understanding Selectivity of Nuclear Hormone Receptors PXR, CAR, FXR, LXRa, and LXRb. Pharm. Res. 2002, 19, 1788-1800.
62. Dussault, I.; Lin, M.; Hollister, K.; Fan, M.; Termini, J.; Sherman, M. A.; Forman, B. M. A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity. Mol. Cell. Biol. 2002, 22, 5270-5280.
63. Xiao, L.; Cui, X.; Madison, V.; White, R. E.; Cbeng, K. C. Insights from a three-dimensional model into ligand binding to constitutive active receptor. Drug Metab. Dispos. 2002, 30, 951-956.
64. Windshuegel, B.; Jyrkkaerinne, J.; Poso, A.; Honkakoski, P.; Sippl, W. Molecular dynamics simulations of the human CAR ligand-binding domain: Deciphering the molecular basis for constitutive activity. J. Mol. Model. (Online) 2005, 11, 69-79.
65. Jyrkkarinne, J.; Windshugel, B.; Makinen, J.; Ylisirnio, M.; Perakyla, M.; Poso, A.; Sippl, W.; Honkakoski, P. Amino acids important for ligand specificity of the human constitutive androstane receptor. J. Biol. Chem. 2005, 280, 5960-5971.
66. Suino, K.; Peng, L.; Reynolds, R.; Li, Y.; Cha, J.-Y.; Repa, J. J.; Kliewer, S. A.; Xu, H. E. The nuclear xenobiotic receptor CAR: Structural determinants of constitutive activation and heterodimerization. Mol. Cell 2004, 16, 893-905.
67. Shulman A. I.; Mangelsdorf, D. J. Retinoid X receptor heterodimers m the metabolic syndrome. N. Engl. J. Med. 2005, 353, 604-615.
68. Pellicciari, R.; Costantino, G.; Fiorucci, S. Farnesoid X Receptor: From Structure to Potential Clinical Applications. J. Med. Chem. 2005, 48, 5383-5403.
69. Fujino, T.; Une, M.; Imanaka, T.; Inoue, K.; Nishimaki-Mogami, T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. J. Lipid Res. 2004, 45, 132-138.
70. Pellicciari, R.; Costantino, G.; Camaioni, E.; Sadeghpour, B. M.; Entrena, A.; Willson, T. M.; Fiorucci, S.; Clerici, C.; Gioiello, A. Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid. J. Med. Chem. 2004, 47, 4559-4569.
71. Tripos HQSAR: St. Louis, MO.
72. Honorio, K. M.; Garratt, R. C.; Andricopulo, A. D. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators. Bioorg. Med. Chem. Lett. 2005, 15, 3119-3125.
73. Janowski, B. A.; Grogan, M. J.; Jones, S. A.; Wisely, G. B.; Kliewer, S. A.; Corey, E. J.; Mangelsdorf, D. J. Structural requirements of ligands for the oxysterol liver X receptors LXRa and LXRb. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 266-271.
74. Spencer, T. A.; Li, D.; Russel, J. S.; Collins, J. L.; Bledsoe, R. K.; Consler, T. G.; Moore, L. B.; Galardi, C. M.; McKee, D. D.; Moore, J. T.; Watson, M. A.; Parks, D. J.; Lambert, M. H.; Willson, T. M. Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXRa. J. Med. Chem. 2001, 44, 886-897.
75. Urban, F., Jr.; Cavazos, G.; Dunbar, J.; Tan, B.; Escher, P.; Tafuri, S.; Wang, M. The important role of residue F268 in ligand binding by LXRb. FEBS Lett. 2000, 484, 159-163.
76. Wang, M.; Thomas, J.; Burris, T. P.; Schkeryantz, J.; Michael, L. F. Molecular determinants of LXRa agonism. J. Mol. Graph. Model. 2003, 22, 173-181.
77. Saarikoski, S. T.; Rivera, S. P.; Hankinson, O.; Husgafvel-Pursianen, K. CYP2S1: A short review. Toxicol. Appl. Pharmacol. 2005, 207, S62-S69.
78. Ramadoss, P.; Marcus, C.; Perdew, G. H. Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin. Drug Metab. Toxicol. 2005, 1, 9-21.
79. Pocar, P.; Fischer, B.; Klonisch, T.; Hombach-Klonisch, S. Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. Reproduction 2005, 129, 379-389.
80. Hankinson, O. Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch. Biochem. Biophys. 2005, 433, 379-386.
81. Mandal, P. K. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J. Comp. Physiol. B, Biochem. Syst. Environ. Physiol. 2005, 175, 221-230.
82. Okey, A. B.; Franc, M. A.; Moffat, I. D.; Tijet, N.; Boutros, P. C.; Korkalainen, M.; Tuomisto, J.; Pohjanvirta, R. Toxicological implications of polymorphisms in receptors for xenobiotic chemicals: The case of the aryl hydrocarbon receptor. Toxicol. Appl. Pharmacol. 2005, 207, S43-S51.
83. Hombach-Klonisch, S.; Pocar, P.; Kietz, S.; Klonisch, T. Molecular actions of polyhalogenated arylhydrocarbons (PAHs) in female reproduction. Curr. Med. Chem. 2005, 12, 599-616.
84. Karp, J. M.; Rodrigo, K. A.; Pei, P.; Pavlick, M. D.; Andersen, J. D.; McTigue, D. J.; Fields, H. W.; Mallery, S. R. Sanguinarine activates polycyclic aromatic hydrocarbon associated metabolic pathways in human oral keratinocytes and tissues. Toxicol. Lett. 2005, 158, 50-60.
85. Westwell, A. D. The therapeutic potential of aryl hydrocarbon receptor (AhR) agonists in anticancer drug development. Drugs Future 2004, 29, 479-491.
86. Mehrabi, M. R.; Steiner, G. E.; Dellinger, C.; Kofler, A.; Schaufler, K.; Tamaddon, F.; Plesch, K.; Ekmekcioglu, C.; Maurer, G.; Glogar, H. D.; Thalhammer, T. The arylhydrocarbon receptor (AhR), but not the AhR-nuclear translocator (ARNT), is increased in hearts of patients with cardiomyopathy. Virchows Arch. 2002, 441, 481-489.
87. Caprioara, M.; Diudea, M. V. QSAR modeling of polychlorinated aromatic compounds. Indian J. Chem. 2003, 42A, 1368-1378.
88. Saeki, K.-i.; Matsuda, T.; Kato, T.-a.; Yamada, K.; Mizutani, T.; Matsui, S.; Fukuhara, K,; Miyata, N. Activation of the human Ah receptor by aza-polycyclic aromatic hydrocarbons and their halogenated derivatives. Biol. Pharm. Bull. 2003, 26, 448-452.
89. Kato, T.-a.; Matsuda, T.; Matsui, S.; Mizutani, T.; Saeki, K.-i. Activation of the aryl hydrocarbon receptor by methyl yellow and related congeners: Structure-activity relationships in halogenated derivatives. Biol. Pharm. Bull. 2002, 25, 466-471.
90. Lewis, D. F. V.; Jacobs, M. N. A QSAR study of some PCBs' ligand-binding affinity to the cytosolic Ali receptor (AhR). Organolialogen Cmpounds 1999, 41, 537-540.
91. Vetter, W.; Hahn, M. E.; Tomy, G.; Ruppe, S.; Vatter, S.; Chahbane, N.; Lenoir, D.; Schramm, K. W.; Scherer, G. Biological Activity and Physicochemical Parameters of Marine Halogenated Natural Products 2,3,3_pm,4,4_pm,5,5_pm-Heptachloro-l_pm-Methyl-1,2_pm-Bipyrrole and 2,4,6-Tribromoanisole. Arch. Environ. Contam. Toxicol. 2005, 48, 1-9.
92. Beger, R. D.; Buzatu, D. A.; Wilkes, J. G. Combining NMR spectral and structural data to form models of polychlorinated dibenzodioxins, dibenzofurans, and biphenyls binding to the AhR. J. Comput. Aided Mol. Des. 2002, 16, 727-740.
93. Denison, M. S.; Nagy, S. R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 309-334.
94. Denison, M. S. Exactly the same but different: Analysis and implications of the promiscuity of ligand-dependent activation of the Ah receptor signaling pathway. Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, 2005; pp AGRO-050.
95. Backlund, M.; Ingelman-Sundberg, M. Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Mol. Pharmacol. 2004, 65, 416-425.
96. Procopio, M.; Lahm, A.; Tramomano, A.; Bonati, L.; Pitea, D. Homology modeling of the AhR ligand binding domain. Organohalogen Compounds 1999, 42, 405-408.
97. Runge-Morris, M.; Kocarek, T. A. Regulation of sulfotransferases by xenobiotic receptors. Curr. Drug. Metab. 2005, 6, 299-307.
98. Radominska-Pandya, A.; Mackenzie, P. I.; Xie, W. Transcriptional regulation of UDP-glucuronosyltransferases. In Drug Metabolism and Transport; Lash, L. H.; Eds.; Humana Press Inc.: Totowa, NJ, 2005; pp 133-171.
99. Tan, N. S.; Michalik, L.; Desvergne, B.; Wahli, W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J. Steroid Biochem. Mol. Biol. 2005, 93, 99-105.
100. Mandard, S.; Mueller, M.; Kersten, S. Peroxisome proliferator-activated receptor a target genes. Cell. Mol. Life Sci. 2004, 61, 393-416.
101. Kiec-Wilk, B.; Dembinska-Kiec, A.; Olszanecka, A.; Bodzioch, M.; Kawecka-Jaszcz, K. The selected pathophysiological aspects of PPARs activation. J. Physiol. Pharmacol. 2005, 56, 149-162.
102. Boitier, E.; Gautier, J.-C.; Roberts, R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: Relevance for human health and disease. Comp. Hepatol. 2003, 2, 3.
103. Schramm, C.; Roberts, R. A. PPAR-a ligands: benefits and mechanistic cancer risk assessment. Recent Res. Develop. Cancer 2002, 4, 569-589.
104. Wang, J.; Hu, X.; Shi, J. Regulation of apoptosis by peroxisome proliferator activated receptors. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2004, 26, 357-361.
105. Cunard, R. The potential use of PPARa agonists as immunosuppressive agents. Curr. Opin. Investig. Drugs 2005, 6, 467-472.
106. Erol, A. PPARa activators may be good candidates as antiaging agents. Med. Hypotheses 2005, 65, 35-38.
107. Saeed, S. A.; Choudhary, M. I.; Fatima, K.; Zubairi, A. J.; Manzoor, I.; Gitay, M. N.; Saeed, S. New prospects in the understanding of molecular basis of ageing. J. Biol. Sci. (Faisalabad) 2005, 5, 38-43.
108. Di-Poi, N.; Michalik, L.; Desvergne, B.; Wahli, W. Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeristasis. Lipids 2004, 39, 1093-1099.
109. Staels, B.; Fruchart, J.-C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54, 2460-2470.
110. LoVerme, J.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The search for the palmitoylethanolamide receptor. Life Sci. 2005, 77, 1685-1698.
111. Lewis, D. F. V.; Jacobs, M. N.; Dickins, M.; Lake, B. G. Quantitative structure-activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. Toxicology 2002, 176, 51-57.
112. Pirard, B. Peroxisome Proliferator-Activated Receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis. J. Commit. Aided Mol. Des. 2004, 17, 785-796.
113. Khanna, S.; Sobhia, M. E.; Bharatam, P. V. Additivity of Molecular Fields: CoMFA Study on Dual Activators of PPARa and PPARg. J. Med Chem. 2005, 48, 3015-3025.
114. Uchiki, H.; Miyachi, H. Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) a agonist; possible mechanism(s) of human PPARa selectivity of an a-substituted phenylpropanoic acid derivative (KCL). Chem. Pharm. Bull. 2004, 52, 365-367.
115. Nomura, M.; Tanase, T.; Ide, T.; Tsunoda, M.; Suzuki, M.; Uchiki, H.; Murakami, K.; Miyachi, H. Design, Synthesis, and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Human Peroxisome Proliferator Activated Receptor Activators. Discovery of Potent and Human Peroxisome Proliferator Activated Receptor a Subtype-Selective Activators. J. Med. Chem. 2003, 46, 3581-3599.
116. Yue, L.; Ye, F.; Xu, X.; Shen, J.; Chen, K.; Shen, X.; Jiang, H. The conserved residue Phe273(282) of PPARa(g), beyond the ligand-binding site, functions in binding affinity through solvation effect. Biochimie 2005, 87, 539-550.
117. Wang, M.; Winneroski, L. L.; Ardecky, R. J.; Babine, R. E.; Brooks, D. A.; Etgen, G. J.; Hutchison, D. R.; Kauffman, R. F.; Kunkel, A.; Mais, D. E.; Montrose-Rafizadeh, C.; Ogilvie, K. M.; Oldham, B. A.; Peters, M. K.; Rito, C. J.; Rungta, D. K.; Tripp, A. E.; Wilson, S. B.; Xu, Y.; Zink, R. W.; McCarthy, J. R. Conversion of human-selective PPARa agonists to human/mouse dual agonists: a molecular modeling analysis. Bioorg. Med. Chem. Lett. 2004, 14, 6113-6116.
118. Hostetler, H. A.; Petrescu, A. D.; Kier, A. B.; Schroeder, F. Peroxisome Proliferator-activated Receptor a Interacts with High Affinity and Is Conformationally Responsive to Endogenous Ligands. J. Biol. Chem. 2005, 280, 18667-18682.
119. Pinelli, A.; Godio, C.; Laghezza, A.; Mitro, N.; Fracchiolla, G.; Tortorella, V.; Lavecchia, A.; Novellino, E.; Fruchart, J.-C.; Staels, B.; Crestani, M.; Loiodice, F. Synthesis, Biological Evaluation, and Molecular Modeling Investigation of New Chiral Fibrates with PPARa and PPARg Agonist Activity. J. Med. Chem. 2005, 48, 5509-5519.
120. Barker, M.; Clackers, M.; Demaine, D. A.; Humphreys, D.; Johnston, M. J.; Jones, H. T.; Pacquet, F.; Pritchard, J. M.; Salter, M.; Shanahan, S. E.; Skone, P. A.; Vinader, V. M.; Uings, I.; McLay, I. M.; Macdonald, S. J. F. Design and Synthesis of New Nonsteroidal Glucocorticoid Modulators through Application of an \"Agreement Docking\" Method. J. Med. Chem. 2005, 48, 4507-4510.
121. Kumar, R.; Thompson, E. B. Gene regulation by the glucocorticoid receptor: Structure:function relationship. J. Steroid Biochem. Mol. Biol. 2005, 94, 383-394.
122. Bledsoe, R. K.; Stewart, E. L.; Pearce, K. H. Structure and function of the glucocorticoid receptor ligand binding domain. Vitam. Horm. 2004, 68, 49-91.
123. Peeters, B. W. M. M.; Tonnaer, J. A. D. M.; Groen, M. B.; Broekkamp, C. L. E.; van der Voort, H. A. A.; Schoonen, W. G. F. J.; Smets, R. J. M.; Vanderheyden, P. M. L.; Gebhard, R.; Ruigi, G. S. F. Short Review: Glucocorticoid Receptor Antagonists: New Tools to Investigate Disorders Characterized by Cortisol Hypersecretion. Stress 2004, 7, 233-241.
124. Einstein, M.; Greenlee, M.; Rouen, G.; Sitlani, A.; Santoro, J.; Wang, C.; Pandit, S.; Mazur, P.; Smalera, I.; Weaver, A. P. M.; Zeng, Y. Y.; Ge, L.; Kelly, T.; Paiva, T.; Geissler, W.; Mosley, R. T.; Williamson, J.; Ali, A.; Balkovec, J.; Harris, G. Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism. J. Steroid Biochem. Mol. Biol. 2004, 92, 345-356.
125. Heikinheimo, O. Clinical pharmacokinetics of mifepristone. Clin. Pharmacokinet. 1997, 33, 7-17.
126. Von Geldern, T. W.; Link, J. T.; Tu, N.; Kym, P. I-; Lai, C.; Richards, S. J.; Jacobson, P. B.; Bishop, R. D.; Gates, B. D. Preparation of cholic acid derivatives for therapeutic use as glucocorticoid receptor ligands for the treatment of metabolic disorders. Wo 2004000869, 2003.
127. Gillner, M.; Hagberg, L.; Koch, E.; Nilsson, M.; Wu, J. Preparation of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor III. PCT Int. Appl. 2002044120, 2002.
128. Apelqvist, T.; Gillner, M.; Gustavsson, A.; Hagberg, L.; Koch, E.; Lindberg, M.; Pelcman, B.; Wu, J.; Kym, P. R. Preparation of diphenyl ethers as liver selective glucocorticoid receptor antagonists. PCT Int. Appl. 2001047859, 2001.
129. Chrousos, G. P. The glucocorticoid receptor gene, longevity, and the complex disorders of Western societies. Am. J. Med 2004, 117, 204-207.
130. Rosmond, R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes. Res. 2002, 10, 1078-1086.
131. Lewis, D. F. V.; Ogg, M. S.; Goldfarb, P. S.; Gibson, G. G. Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor a (hERa) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement. J Steroid Biochem. Mol. Biol. 2002, 82, 195-199
132. Dey, R.; Roychowdhury, P.; Mukherjee, C. Homology modelling of the ligand-binding domain of glucocorticoid receptor: binding site interactions with cortisol and corticosterone. Protein Eng. 2001, 14, 565-571
133. Gillner, M.; Greenidge, P. Homology models of the glucocorticoid receptor. PCT Int. Appl. 2000052050, 2000.
134. Apolito, C. J.; Bledsoe, R. K.; Lambert, M. H., III; McKee, D. D.; Montana, V. G.; Pearce, K. H.; Stanley, T. B.; Xu, H. E. Crystal structure of ligand-binding domain of human glucocorticoid. receptor a and is use in screening assays and molecular modeling of related nuclear receptors. PCT Int. Appl. 2003015692, 2003.
135. Carlsson, P.; Koehler, K. F.; Nilsson, L. Glucocorticoid receptor point mutation V571M facilitates coactivator and ligand binding by structural rearrangement and stabilization. Mol. Endocrinol. 2005, 19, 1960-1977.
136. Stockner, T.; Sterk, H.; Kaptein, R.; Bonvin, A. M. J. J. Molecular Dynamics Studies of a Molecular Switch in the Glucocorticoid Receptor. J. Mol. Biol. 2003. 328, 325-334
137. Betageri, R.; Zhang, Y.; Zindell, R. M.; Kuzmich, D.; Kirrane, T. M.; Bentzien, J.; Cardozo, M.; Capolino, A. J.; Fadra, T. N.; Nelson, R. M.; Paw, Z.; Shih, D.-T.; Shih, C.-K.; Zuvela-Jelaska, L.; Nabozny, G.; Thomson, D. S. Trifluoromethyl group as a pharmacophore: Effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand. Bioorg. Med. Chem. Lett. 2005, 15, 4761-4769.
138. Bredenberg, J.; Nilsson, L. Conformational states of the glucocorticoid receptor DNA-binding domain from molecular dynamics simulations. Proteins 2002, 49, 24-36.
139. Hertz, R.; Magenheim, J.; Berman, I.; Bar-Tana, J. Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4a. Nature 1998, 392, 512-516.
140. Khan, S. A.; Vanden Heuvel, J. P. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J. Nutr. Biochem. 2003, 14, 554-567.
141. Black, P. N.; Faergeman, N. J.; DiRusso, C. C. Long-chain Acyl-CoA-dependent regulation of gene expression in bacteria, yeast and mammals. J. Nutr. 2000, 130, 305S-309S.
142. Sampath, H.; Ntambi, J. M. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu. Rev. Nutr. 2005, 25, 317-340.
143. Petrescu, A. D.; Hertz, R.; Bar-Tana, J.; Schroeder, F.; Kier, A. B. Role of Regulatory F-domain in Hepatocyte Nuclear Factor-4a Ligand Specificity. J. Biol. Chem. 2005, 280, 16714-16727.
144. Sladek, F. M.; Ruse, M. D., Jr.; Nepomuceno, L.; Huang, S.-M.; Stallcup, M. R. Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4a1. Mol. Cell. Biol. 1999, 19, 6509-6522.
145. Peiler, G.; Bockmann, B.; Nakhei, H.; Ryffel, G. U. Inhibitor of the tissue-specific transcription factor BNF4, a potential regulator in early Xenopus development. Mol. Cell. Biol. 2000, 20, 8676-8683.
146. Barbier, O.; Girard, H.; Inoue, Y.; Duez, H.; Villeneuve, L.; Kamiya, A.; Fruchart, J.-C.; Guillemette, C.; Gonzalez, F. J.; Staels, B. Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4a. Mol. Pharmacol. 2005, 67, 241-249.
147. Yamagata, K.; Furuta, H.; Oda, N.; Kaisaki, P. J.; Menzel, S.; Cox, N. J.; Fajans, S. S.; Signorini, S.; Stoffel, M.; Bell, G. I. Mutations in the hepatocyte nuclear factor-4a gene in maturity-onset diabetes of the young (MODY1). Nature 1996, 384, 458-460.
148. Bulman, M. P.; Dronsfield, M. J.; Frayling, T.; Appleton, M.; Bain, S. C.; Ellard, S.; Hattersley, A. T. A missense mutation in the hepatocyte nuclear factor 4 alpha gene in a UK pedigree with maturity-onset diabetes of the young. Diabetologia 1997, 40, 859-862.
149. Sladek, F. M.; Dallas-Yang, Q.; Nepomuceno, L. MODY1 mutation Q268X in hepatocyte nuclear factor 4a allows for dimerization in solution but causes abnormal subcellular localization. Diabetes 1998, 47, 985-990.
150. Wisely, G. B.; Miller, A. B.; Davis, R. G.; Thornquest, A. D.; Johnson, R.; Spitzer, T.; Sefler, A.; Shearer, B.; Moore, J. T.; Miller, A. B.; Willson, T. M.; Williams, S. P. Hepatocyte Nuclear Factor 4 Is a Transcription Factor that Constitutively Binds Fatty Acids. Structure 2002, 10, 1225-1234.
151. Dhe-Paganon, S.; Duda, K.; Iwamoto, M.; Chi, Y.-I.; Shoelson, S. E. Crystal Structure of the HNF4a Ligand Binding Domain in Complex with Endogenous Fatty Acid Ligand. J. Biol. Chem. 2002, 277, 37973-37976.
152. Eeckhoute, J.; Oxombre, B.; Formstecher, P.; Lefebvre, P.; Laine, B. Critical role of charged residues in bea 7 of the ligand binding domain in Hepatocyte Nuclear Factor 4a dimerization and transcriptional activity. Nucleic Acids Res. 2003, 31, 6640-6650.
153. Aggelidou, E.; Iordanidou, P.; Tsantili, P.; Papadopoulos, G.; Hadzopoulou-Cladaras, M. Critical Role of Residues Defining the Ligand Binding Pocket in Hepatocyte Nuclear Factor-4a. J. Biol. Chem. 2004, 279, 30680-30688.
154. Podvinec, M.; Kaufmann, M. R.; Handschin, C.; Meyer, U. A. NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol. Endocrinol. 2002, 16, 1269-1279.
155. Kel, A.; Reymann, S.; Matys, V.; Nettesheim, P.; Wingender, E.; Borlak, J. A novel computational approach for the prediction of networked transcription factors of aryl hydrocarbon-receptor-regulated genes. Mol. Pharmacol. 2004, 66, 1557-1572.